Respiratory syncytial virus vaccine(Moderna Therapeutics)

Moderna has voluntarily withdrawn its Biologics License Application (BLA) for mRNA-1083, a combination flu and COVID-19 vaccine candidate for adults 50 and older, after consultation with the FDA.

Moderna's mRESVIA vaccine received MHRA approval in February 2025 for adults aged 60 and older, joining GSK's Arexvy and Pfizer's Abrysvo in the expanding RSV vaccine market.

Genevant Sciences and Arbutus Biopharma have filed five international lawsuits against Moderna, targeting alleged patent infringement of their lipid nanoparticle (LNP) technology in 30 countries.

Insulin icodec, a once-weekly basal insulin analog, demonstrated positive safety and efficacy in phase 3 trials for type 2 diabetes, potentially reducing injection burden and improving adherence.

Moderna reported $3.2 billion in total revenue for fiscal year 2024, with a net loss of $3.6 billion as the company transitions from pandemic to seasonal COVID-19 vaccine market.